|
ZA200602755B
(en)
|
2003-09-06 |
2007-06-27 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
|
JP4869072B2
(ja)
*
|
2003-11-14 |
2012-02-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
LT2502911T
(lt)
*
|
2004-06-24 |
2017-09-11 |
Vertex Pharmaceuticals Incorporated |
Atp surišančios kasetės transporterių moduliatoriai
|
|
ATE512145T1
(de)
|
2005-08-11 |
2011-06-15 |
Vertex Pharma |
Modulatoren des cystic fibrosis transmembrane conductance regulators
|
|
EP1945632B1
(en)
|
2005-11-08 |
2013-09-18 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic modulators of atp-binding cassette transporters
|
|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
AU2006336504C9
(en)
*
|
2005-12-28 |
2015-05-14 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
NZ571803A
(en)
|
2006-04-07 |
2011-12-22 |
Vertex Pharma |
Amide indole derivatives as modulators of ATP-binding cassette transporters
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8563573B2
(en)
*
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
US8969386B2
(en)
|
2007-05-09 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
|
HUE028426T2
(en)
*
|
2007-08-24 |
2016-12-28 |
Vertex Pharma |
Isothiazolopyridinones for (inter alia) treating cystic fibrosis
|
|
AU2008298545B2
(en)
*
|
2007-09-14 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
SI2217572T1
(sl)
*
|
2007-11-16 |
2014-05-30 |
Vertex Pharmaceuticals Incorporated |
Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
|
|
EP2639224B1
(en)
|
2007-12-07 |
2016-08-24 |
Vertex Pharmaceuticals Incorporated |
Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
|
|
SI2225230T1
(sl)
|
2007-12-07 |
2017-03-31 |
Vertex Pharmaceuticals Incorporated |
Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
|
|
WO2009076141A2
(en)
*
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
JP5637859B2
(ja)
*
|
2007-12-13 |
2014-12-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
|
|
NZ720282A
(en)
|
2008-02-28 |
2017-12-22 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
|
EP2271621B1
(en)
*
|
2008-03-31 |
2013-11-20 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as cftr modulators
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
JP2012504143A
(ja)
*
|
2008-09-29 |
2012-02-16 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
|
|
NZ592685A
(en)
*
|
2008-10-23 |
2013-04-26 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP2382197B1
(en)
*
|
2008-12-30 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
HRP20160682T1
(hr)
|
2010-04-07 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
|
|
HRP20211752T1
(hr)
|
2010-04-07 |
2022-02-18 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
|
|
ES2608474T3
(es)
|
2010-04-22 |
2017-04-11 |
Vertex Pharmaceuticals Incorporated |
Proceso de producción de compuestos indol cycloalkylcarboxamido
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
IN2014KN00885A
(enExample)
|
2011-11-08 |
2015-10-02 |
Vertex Pharma |
|
|
WO2013112804A1
(en)
|
2012-01-25 |
2013-08-01 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
WO2014014841A1
(en)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
EP2994139B1
(en)
|
2013-05-10 |
2019-04-10 |
Gilead Apollo, LLC |
Acc inhibitors and uses thereof
|
|
JP6417402B2
(ja)
|
2013-05-10 |
2018-11-07 |
ギリアド アポロ， エルエルシー |
Ａｃｃ阻害剤及びその使用
|
|
AU2014262547A1
(en)
|
2013-05-10 |
2015-11-26 |
Gilead Apollo, Llc |
ACC inhibitors and uses thereof
|
|
JP6417401B2
(ja)
*
|
2013-05-10 |
2018-11-07 |
ギリアド アポロ， エルエルシー |
Ａｃｃ阻害剤及びその使用
|
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
|
|
ES2885181T3
(es)
|
2014-04-15 |
2021-12-13 |
Vertex Pharma |
Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
|
|
AR100706A1
(es)
|
2014-06-03 |
2016-10-26 |
Novartis Ag |
Derivados de naftiridinadiona
|
|
KR20170063954A
(ko)
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
|
JP6615213B2
(ja)
|
2014-10-31 |
2019-12-04 |
アッヴィ・エス・ア・エール・エル |
置換テトラヒドロピランおよび使用方法
|
|
PT3221692T
(pt)
|
2014-11-18 |
2021-09-10 |
Vertex Pharma |
Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
|
|
KR20180029204A
(ko)
|
2015-06-02 |
2018-03-20 |
애브비 에스.에이.알.엘. |
치환된 피리딘 및 사용 방법
|
|
US9840513B2
(en)
*
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
US10130622B2
(en)
|
2015-10-09 |
2018-11-20 |
Abbvie S.Á.R.L. |
Compounds for treatment of cystic fibrosis
|
|
RU2724345C2
(ru)
|
2015-10-09 |
2020-06-23 |
Галапагос Нв |
N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
|
|
AU2016333855A1
(en)
|
2015-10-09 |
2018-04-26 |
AbbVie S.à.r.l. |
Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
EP3558982A1
(en)
|
2016-12-20 |
2019-10-30 |
AbbVie S.À.R.L. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
EP3747882A1
(en)
|
2019-06-03 |
2020-12-09 |
AbbVie Overseas S.à r.l. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
TW202115014A
(zh)
|
2019-07-12 |
2021-04-16 |
美商奧佛麥德公司 |
用於治療囊腫纖維化之化合物
|
|
WO2021052797A1
(en)
|
2019-09-20 |
2021-03-25 |
Sabic Global Technologies B.V. |
Compounds for use in catalyst compositions for the production of polyolefins
|
|
EP4058434A1
(en)
|
2019-11-12 |
2022-09-21 |
Genzyme Corporation |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022150173A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2022150174A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
CA3230259A1
(en)
|
2021-09-03 |
2023-03-09 |
Junkai Liao |
Indole compounds and methods of use
|
|
EP4396176A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
KR20250091331A
(ko)
|
2022-09-07 |
2025-06-20 |
시오나 테라퓨틱스 인크. |
거대환식 화합물, 조성물, 및 이의 사용 방법
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|